Thus, although genetic-driven tumour profiling is similar to that of IPF-free LC, as documented by EGFR behaviour and asset, the immune tumour status should be strictly related to the surrounding IPF stroma and the clinicopathologic features of the interstitial diseases. The gene discussed is EGFR; the disease is neoplasm.